Twenty years of triptans in the United States Medicaid programs: Utilization and reimbursement trends from 1993 to 2013.

Objective: After sumatriptan was approved by the Food and Drug Administration in 1992, triptans became first-line anti-migraine therapies. Rapidly rising triptan expenditures, however, led payers, including Medicaid, to implement cost-containment policies. We describe triptan utilization and reimbursement trends in Medicaid.

Utilization and spending trends for antiretroviral medications in the U.S. Medicaid program from 1991 to 2005.

Background: HIV/AIDS incidence and mortality rates have decreased in the U.S. since 1996.

Lethal drug probe in China: the case of Xinfu clindamycin.

In China, antibiotics are prescribed frequently, not only for bacterial infections but also for viruses, including the common cold, as well as other illnesses.12 Chinese people tend to believe that antibiotics are a cure for many diseases from skin infections to life-threatening lung ailments; and antibiotics are their first choice when they think about buying medication.3 Antibiotic abuse is particularly severe in small- and medium-sized towns and rural areas where doctors are not as well educated as in the large cities.